Scholarlink

Introduction <p>Lenvatinib was authorized for use as a first-line medication for unresectable hepatocellular carcinoma (HCC). This study examined the safety and efficacy of lenvatinib in a cohort of Egyptian patients with HCC in a real-world context.</p> Methods <p>We performed a prospective cohort study for lenvatinib-treated advanced HCC (from June 2023 to March 2024) with follow-up extending until December 2024. Demographic characteristics, tumor features, lenvatinib dosage, adverse events (AEs), and tumor response were gathered. The main objective was overall survival (OS).</p> Results <p>This longitudinal cohort research comprised 23 patients with cirrhosis. The majority of patients were male (91.3%), with a median age of 65&#xa0;years. 65.2% were attributable to hepatitis C. Nine patients (39.1%) were administered lenvatinib at a dosage of 8&#xa0;mg/day, whereas 14 patients (60.9%) received a dosage of 12&#xa0;mg/day. The median treatment duration was 70&#xa0;days (IQR: 48–177). Adverse events occurred in 16 patients (72.7%). Elevated liver enzymes occurred most frequently at 34.8%, followed by jaundice at 17.3%. Grade 3 AEs were documented in 7 patients (43.75%).</p> <p>By the study end, seven individuals (30.43%) had succumbed. Eight patients (34.78%) exhibited stable disease, whereas three individuals (13.04%) demonstrated progressing disease. The median survival, as determined by the Kaplan–Meier curve, was 14.16&#xa0;months. OS exhibited a substantial positive correlation with treatment duration (<i>r</i> = 0.664, <i>p</i>-value = 0.001). Multivariate COX analysis indicated that the Child–Pugh score was the independent variable correlated with increased mortality (hazard ratio 8.001, 95% confidence interval 1.312–48.803, <i>P</i>-value 0.024).</p> Conclusion <p>Lenvatinib is a safe and well-tolerated therapeutic option for Egyptian patients eligible for systemic treatment of HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of lenvatinib therapy for advanced hepatocellular carcinoma: a real-world Egyptian cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月27日

查看全文
  • Ahmed Radwan Riad,
  • Hend Ibrahim Shousha,
  • Mohamed Omar Abdelmalek,
  • Nariman Zaghloul,
  • Sara Mahrous,
  • Gamal Esmat,
  • Mohamed Hassany,
  • Mohamed Abdallah,
  • Ehab Fawzy Mostafa

摘要

Introduction

Lenvatinib was authorized for use as a first-line medication for unresectable hepatocellular carcinoma (HCC). This study examined the safety and efficacy of lenvatinib in a cohort of Egyptian patients with HCC in a real-world context.

Methods

We performed a prospective cohort study for lenvatinib-treated advanced HCC (from June 2023 to March 2024) with follow-up extending until December 2024. Demographic characteristics, tumor features, lenvatinib dosage, adverse events (AEs), and tumor response were gathered. The main objective was overall survival (OS).

Results

This longitudinal cohort research comprised 23 patients with cirrhosis. The majority of patients were male (91.3%), with a median age of 65 years. 65.2% were attributable to hepatitis C. Nine patients (39.1%) were administered lenvatinib at a dosage of 8 mg/day, whereas 14 patients (60.9%) received a dosage of 12 mg/day. The median treatment duration was 70 days (IQR: 48–177). Adverse events occurred in 16 patients (72.7%). Elevated liver enzymes occurred most frequently at 34.8%, followed by jaundice at 17.3%. Grade 3 AEs were documented in 7 patients (43.75%).

By the study end, seven individuals (30.43%) had succumbed. Eight patients (34.78%) exhibited stable disease, whereas three individuals (13.04%) demonstrated progressing disease. The median survival, as determined by the Kaplan–Meier curve, was 14.16 months. OS exhibited a substantial positive correlation with treatment duration (r = 0.664, p-value = 0.001). Multivariate COX analysis indicated that the Child–Pugh score was the independent variable correlated with increased mortality (hazard ratio 8.001, 95% confidence interval 1.312–48.803, P-value 0.024).

Conclusion

Lenvatinib is a safe and well-tolerated therapeutic option for Egyptian patients eligible for systemic treatment of HCC.